Compare, Analyse Aurobindo Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MYLAN (US) - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 AUROBINDO PHARMA   MYLAN
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-19
MYLAN
Dec-18
AUROBINDO PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8303,410-   
Low Rs5271,877-   
Sales per share (Unadj.) Rs333.91,568.9-  
Earnings per share (Unadj.) Rs40.442.6-  
Cash flow per share (Unadj.) Rs51.8336.4-  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs237.11,697.3-  
Shares outstanding (eoy) m585.91514.50-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.01.7 120.6%   
Avg P/E ratio x16.862.0 27.1%  
P/CF ratio (eoy) x13.17.9 166.8%  
Price / Book Value ratio x2.91.6 183.8%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m397,5691,359,899 29.2%   
No. of employees `00017.935.0 51.0%   
Total wages/salary Rs m25,8490-   
Avg. sales/employee Rs Th10,956.923,062.8 47.5%   
Avg. wages/employee Rs Th1,447.70-   
Avg. net profit/employee Rs Th1,324.3626.3 211.5%   
INCOME DATA
Net Sales Rs m195,636807,198 24.2%  
Other income Rs m1,5530-   
Total revenues Rs m197,189807,198 24.4%   
Gross profit Rs m39,519208,873 18.9%  
Depreciation Rs m6,680151,139 4.4%   
Interest Rs m2,62638,823 6.8%   
Profit before tax Rs m31,76718,910 168.0%   
Minority Interest Rs m270-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-8810-   
Tax Rs m7,269-3,008 -241.6%   
Profit after tax Rs m23,64521,919 107.9%  
Gross profit margin %20.225.9 78.1%  
Effective tax rate %22.9-15.9 -143.8%   
Net profit margin %12.12.7 445.1%  
BALANCE SHEET DATA
Current assets Rs m153,645450,739 34.1%   
Current liabilities Rs m120,429328,638 36.6%   
Net working cap to sales %17.015.1 112.2%  
Current ratio x1.31.4 93.0%  
Inventory Days Days13584 161.8%  
Debtors Days Days6493 68.3%  
Net fixed assets Rs m103,909156,583 66.4%   
Share capital Rs m586430 136.3%   
"Free" reserves Rs m138,3220-   
Net worth Rs m138,908873,241 15.9%   
Long term debt Rs m1,800942,508 0.2%   
Total assets Rs m264,5442,342,373 11.3%  
Interest coverage x13.11.5 880.7%   
Debt to equity ratio x01.1 1.2%  
Sales to assets ratio x0.70.3 214.6%   
Return on assets %9.92.6 383.0%  
Return on equity %17.02.5 678.2%  
Return on capital %23.83.2 749.7%  
Exports to sales %49.60-   
Imports to sales %18.80-   
Net fx Rs m56,7270-   
CASH FLOW
From Operations Rs m16,220167,736 9.7%  
From Investments Rs m-28,768-86,701 33.2%  
From Financial Activity Rs m19,191-78,141 -24.6%  
Net Cashflow Rs m6,6561,390 479.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.63 Rs / USD

Compare AUROBINDO PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare AUROBINDO PHARMA With: ABBOTT INDIA  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  ORCHID PHARMA LTD  



Today's Market

Sensex Crashes 807 Points on Coronavirus Fears; Metal and Automobile Stocks Fall(Closing)

Indian share markets fell sharply today, tracking a global selloff as coronavirus cases spiked outside China.

Related Views On News

AUROBINDO PHARMA Plunges by 16%; BSE HEALTHCARE Index Down 1.4% (Market Updates)

Feb 24, 2020 | Updated on Feb 24, 2020

AUROBINDO PHARMA share price has plunged by 16% and its current market price is Rs 540. The BSE HEALTHCARE is down by 1.4%. The top gainers in the BSE HEALTHCARE Index are SHILPA MEDICARE (up 5.0%) and SUVEN LIFESCIENCES (up 4.9%). The top losers is AUROBINDO PHARMA (down 15.6%)..

AUROBINDO PHARMA Plunges by 10%; BSE HEALTHCARE Index Down 0.6% (Market Updates)

Feb 24, 2020 | Updated on Feb 24, 2020

AUROBINDO PHARMA share price has plunged by 10% and its current market price is Rs 540. The BSE HEALTHCARE is down by 0.6%. The top gainers in the BSE HEALTHCARE Index are SUVEN LIFESCIENCES (up 4.9%) and FDC LTD. (up 4.6%). The top losers is AUROBINDO PHARMA (down 10.0%)..

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks (Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

This Smallcap Stock Could be the Next Titan (Up 1,400% in 10 Years) (Profit Hunter)

Feb 11, 2020

A blueprint to latch on to the next 'Crorepati' stock - and an event I hope you won't miss on any account.

Here's Why I Recommended 15 Stocks in One Day Flat Views On News (Views On News)

Feb 14, 2020

This proven strategy can give big returns in quick time.

The Top 8 Trading Mistakes You Should Avoid (Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

These Rebirth of India Stocks Are Raring to Compete with Tesla (The 5 Minute Wrapup)

Feb 17, 2020

There are Indian stocks which can soar like Tesla in the long-run.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Guide on How to Profit from Sensex 100,000.
7 Stocks to Ride the Coming Rebirth of India Rally. Full Details Here...
A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Revealed: Top 7 Stocks to Consider Buying Right Now...

AUROBINDO PHARMA SHARE PRICE


Feb 24, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

OTHER USEFUL LINKS

MARKET STATS